| Ferumoxytol Use as an Intravenous Contrast Agent for Magnetic Resonance Angiography (December). | |
| | |
MedLine Citation:
|
PMID: 22045905 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
OBJECTIVE:To evaluate the efficacy and safety of ferumoxytol for use in magnetic resonance angiography (MRA) of the vasculature.DATA SOURCES:Literature was accessed through MEDLINE (1946-September 2011) and EMBASE (1947-September 2011) using the terms ferumoxytol,magnetic resonance imaging and angiography, blood pool agent, and superparamagnetic iron oxide. Reference citations from identified publications were reviewed for relevant information.STUDY SELECTION AND DATA EXTRACTION:All English-language articles and human studies (N = 9) were identified that evaluated ferumoxytol use in magneticresonance imaging (MRI). Articles that evaluated the use of the drug in first-pass and equilibrium phase imaging of the vasculature were included (n = 4).DATA SYNTHESIS:Contrast agents for MRI improve disease characterization and diagnosis. Ferumoxytol, a medication approved for treatment of iron deficiency anemia in adults with chronic kidney disease, has superparamagnetic properties. As a blood pool agent, ferumoxytol remains primarily in the intravascular space. Therefore, its use in MRI may increase image sensitivity and specificity and have a decreased adverse effect profile compared to other contrast agents. Specifically, ferumoxytol may be an option for MRA, a specific type of MRI that images blood vessels. In the 4 studies evaluated here, ferumoxytol was administered primarily to healthy adults as an accumulative dose of 4 mg Fe/kg injected at 1 mL/sec. Not all studies reported adverse events and addressed safety monitoring. The evaluated studies are limited by small size, open-label design, and noncomparative methodology.CONCLUSIONS:Data from small pilot studies suggest that ferumoxytol may improve image quality in MRA; however, further investigation is necessary to establish its efficacy and safety. Large randomized, active-comparator trials are needed to establish optimal dosing, imaging procedures, and safety monitoring. |
| | |
Authors:
|
Katie L Stabi; Lisa M Bendz |
Related Documents
:
|
17999065 - Mean diffusivity, fractional anisotropy maps, and three-dimensional white-matter tracto... 10391625 - Predicting midsagittal pharynx shape from tongue position during vowel production. 21730385 - Facile synthesis of polymer-enveloped ultrasmall superparamagnetic iron oxide for magne... 17894615 - Diffusion tensor and functional magnetic resonance imaging of diffuse axonal injury and... 22190225 - Theranostic effect of serial manganese-enhanced magnetic resonance imaging of human emb... 16619695 - Primary pancreatic and renal non-hodgkin's lymphoma: ct and mr findings. |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2011-11-1 |
Journal Detail:
|
Title: The Annals of pharmacotherapy Volume: - ISSN: 1542-6270 ISO Abbreviation: - Publication Date: 2011 Nov |
Date Detail:
|
Created Date: 2011-11-2 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9203131 Medline TA: Ann Pharmacother Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Affiliation:
|
< Duke University Hospital, Durham, NC. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Prevnar 13, the New 13-Valent Pneumococcal Conjugate Vaccine (December).
Next Document: Intersection of Quality Metrics and Medicare Policy (December).